We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Blood-Based Control Monitors Immunosuppressant Drug Test Procedures

By Labmedica staff writers
Posted on 17 Jan 2008
A whole blood immunosuppressant control was developed for use as an assayed quality control material to monitor the precision of immunosuppressant drug test procedures in the clinical laboratory from low to very high concentrations. More...


Immunosuppressant drugs are typically used in transplant therapy to help minimize organ rejection. They are also to treat severe skin disorders such as psoriasis and other diseases such as rheumatoid arthritis, Crohn's disease (chronic inflammation of the digestive tract), and patchy hair loss (alopecia areata). Some of these conditions are autoimmune diseases, indicating that the immune system is acting against the body itself.

The new third party, human blood-based control, called Lyphocheck, offers controls for five different immunosuppressive drugs including cyclosporine, tacrolimus, and sirolimus. It can be used with immunoassay or chromatographic techniques.

Lyphocheck was developed by Bio-Rad Laboratories (Hercules, CA, USA), a manufacturer and distributor of clinical diagnostic and life science products. Being a whole blood-based material, Lyphocheck can be processed in the same manner as patient samples, ensuring quality on an ongoing basis.

The Unity Interlaboratory Program and the Unity Real Time, an expert data management software system designed to improve the effectiveness of quality control processes, are available for use with Lyphochek.


Related Links:
Bio-Rad Laboratories

Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Online QC Software
Acusera 24•7
Clinical Informatics Platform
CLARION™
Rapid Sepsis Test
SeptiCyte RAPID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: The study compares rapid molecular CPE diagnostics, which can return results in about one hour, with culture-based screening, which typically takes about 48 hours (Image credit: Adobe Stock)

Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE

Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read more

Industry

view channel
Image: The partnership aims to broaden access to ultrasensitive blood-based testing for multiple myeloma and other hematologic malignancies (Image credit: 123RF)

Partnership Expands Ultrasensitive Blood-Based Diagnostics for Hematologic Malignancies

Predicta Biosciences (Cambridge, MA, USA) and CIMA LAB Diagnostics at Clínica Universidad de Navarra (Pamplona, Spain) have entered an agreement to provide a joint service that combines CIMA LAB’s flow... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.